Our results indicated that Cluster 2, with high expression of ALKBH5 and low expression of YTHDF1, had more immune infiltration, immune checkpoint inhibitor expression, and tumor mutation burden than Cluster 1, hence suggesting that Cluster 2 might respond better to immunotherapy. This evidence concerns the gene ALKBH5 and neoplasm.